(Q46160352)

English

Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients

scientific article published on 17 January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Cytomegalovirus

0 references

1 reference

based on heuristic

inferred from title

cytomegaloviral disease

1 reference

based on heuristic

inferred from title

author name string

Katsuto Takenaka

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Tetsuya Eto

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Koji Nagafuji

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Kenjiro Kamezaki

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Yayoi Matsuo

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Goichi Yoshimoto

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Naoki Harada

7

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Maki Yoshida

8

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Hideho Henzan

9

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Ken Takase

10

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Toshihiro Miyamoto

11

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Koichi Akashi

12

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Mine Harada

13

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Takanori Teshima

14

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Fukuoka Blood and Marrow Transplant Group (FBMTG)

15

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

publication date

17 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

89

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

231-237

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

https://scigraph.springernature.com/pub.10.1007/s12185-008-0249-2

0 references

Risk factors for cytomegalovirus infection after human marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Definitions of cytomegalovirus infection and disease in transplant recipients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What is the optimal dosage of valganciclovir as preemptive therapy for CMV infection in allogeneic hematopoietic SCT?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood a

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-008-0249-2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19148587

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46160352&oldid=2095322231"